Metabool syndroom bij de behandeling met clozapine
January 2009
Article
| Related Files |
|---|
View PDF Version
(Verhoeven_Metabool syndroom.pdf, 0.2MB) |
Abstract Metabolic syndrome during clozapine treatment Objective: To assess the prevalence of metabolic syndrome in inpatients with psychotic disorders treated with clozapine for at least one year. Design: Chronically admitted patients were screened on the use of clozapine and the presence of metabolic side effects. Methods: The Third Adult Treatment Panel was used tot assess metabolic syndrome. In addition, patient variables, dosage and plasma concentration of clozapine were recorded. Results: Included were 62 patients with a most prevalent diagnosis of schizophrenia. Mean duration of treatment with clozapine was 9.2 years. Metabolic syndrome was present in 60% of the patients and more frequent in cases with comedication of mood stabilizers. Conclusion: Metabolic syndrome is highly prevalent among patients treated with clozapine for psychotic disorders. Additional factors in the emergence of metabolic syndrome are: unhealthy life style, inactivity and comedication.
- clozapine
- ënten
- syndroom
- metabool
- diabetes
- syndrome
- patient
- schizophrenia
- antipsychotic
- psychiatry
- mellitu
- tabel
- diabetes mellitus
- treatment
- pati ënten
- antipsychotica
- complicatie
- aantal
- totaal
- suppl
